Authors
Latest:
Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid TumorsA panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.
Latest:
CAR T and Transplantation Advances Across Hematologic Cancers at ASCO 2025An expert panel highlights key presentations in multiple myeloma, lymphoma, and other hematologic malignancies at the 2025 ASCO Annual Meeting.
Latest:
Current Treatment of Burkitt Lymphoma and High-Grade B-Cell LymphomasP. Connor Johnson, MD, and Jeremy S. Abramson MD, MMSc, discuss available treatments for patients with Burkitt lymphoma and high-grade B-cell lymphoma.
Latest:
Exploring the Changing Diagnostic Criteria of Gorlin-Goltz Syndrome: A Case ReportA case study by Sahith Kumar Shetty, BDS, MDS, et al reviews the need for a multidisciplinary approach to the treatment of patients with Gorlin-Goltz syndrome.
Latest:
Which Treatment for Which Patient: Rectal Cancer Management After PROSPECT TrialDetermining treatment options for patients with locally advanced rectal cancer after the PROSPECT trial data readout adds an important level to the decision-making process.
Latest:
Clinical Trial Eligibility and Outcomes in Patients With Metastatic NSCLC Treated Outside of Clinical TrialsThese data support less restrictive clinical trial eligibility criteria for those with metastatic NSCLC. This is especially true regarding both targeted therapy and immunotherapy treatment regimens.
Latest:
Higher MRD Negativity Rates Occur With Isa-RD in Older NDMM PopulationPatients 70 years and older with newly diagnosed multiple myeloma experienced higher response rates and prolonged survival with Isa-Rd vs Rd alone.
Latest:
Clinical Pearls on Recent Advances and the Future of Treatment in RCCMehmet Asim Bilen, MD, summarizes recent advances in metastatic RCC and looks towards the future of the field.
Latest:
Deepu Madduri, MD, on Research in Multiple Myeloma This Past YearThe expert in multiple myeloma spoke about the research that she believes will be most influential for patients with multiple myeloma.
Latest:
Liso-Cel Yields Long-Lasting Complete Responses in Heavily Pretreated MCLTreatment with liso-cel appears to result in clinically meaningful activity across several subgroups of patients with mantle cell lymphoma, including those with high-risk features.
Latest:
Why Sexual and Gender Minority Care Is an Oncologic ImperativeDaniel C. McFarland, DO; and Charles S. Kamen, PhD, MPH, focused on cultural humility, nonverbal data collection, and tailored resources to improve care.
Latest:
Pomalidomide Combo Shows Deep, Enduring Responses in R/R Multiple MyelomaData from the phase 1b MonumenTAL-2 trial support pomalidomide plus talquetamab as a promising treatment option in relapsed/refractory multiple myeloma, says Jeffrey Matous, MD.
Latest:
Undetected MRD Confers Improved PFS With Ibrutinib Combo in CLL/SLLBulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
Latest:
Rare Primary ALK-Positive Anaplastic Large Cell Lymphoma of the Central Nervous SystemAnaplastic large cell lymphoma is a rapidly growing and aggressive hematological malignancy. This case highlights the rarity of isolated intradural extramedullary manifestations in the pediatric population.
Latest:
Elacestrant Regimens Yield Meaningful PFS in ER+/HER2– Breast CancerData from the ELEVATE trial may support elacestrant as an endocrine backbone in ER-positive, HER2-negative breast cancer.
Latest:
Oncology Peer Review On-The-Go: Efficacy of PARP Inhibitors as Maintenance Therapy for Metastatic Castration-Resistant Prostate CancerMuhammad Rafay Khan Niazi, MD, and Alexander Bershadskiy, MD, spoke with CancerNetwork® about the latest research from the journal ONCOLOGY® on the use of PARP inhibitors as maintenance therapy for certain patients with metastatic castration-resistant prostate cancer.
Latest:
Exploring Treatment Options Through Genomic Sequencing in Endometrial CancerRisk factors and biomarker testing in conjunction with cancer staging may better identify ideal treatment for endometrial cancer than cancer staging alone.
